Is overexpression of CD163 and CD47 in tumour cells of breast carcinoma implicated in the recruitment of tumour-associated macrophages (TAMs) in tumour microenvironment? immunohistochemical prognostic study

References

• Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A. A.Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68(6), 394–424. DOI: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Mokhtar, N. A. S.; Badawy, O.; Khorshed, E.; Mohamed , G.; Ibrahim , M.; Abdelazim, H. 2016. Breast cancer. Cancer pathology registry 2000–2011. Cairo, Egypt: National Cancer Institute, Cairo University.
   Google Scholar
• Choi, J.; Gyamfi, J.; Jang, H.; Koo, J. S. The Role of Tumour-Associated Macrophage in Breast Cancer Biology. Histol. Histopathol. 2017, 33(2), 133–145. DOI: 10.14670/HH-11-916.
   PubMed Web of Science ®Google Scholar
• Shabo, I.; Svanvik, J. Expression of Macrophage Antigens by Tumour Cells. In Cell Fusion in Health and Disease; Springer: Dordrecht, 2011; pp. 141–150.
   Google Scholar
• Biswas, S. K.; Allavena, P.; Mantovani, A. Tumour-Associated Macrophages: Functional Diversity, Clinical Significance, and Open Questions. Semin. Immunopathol. 2013, 35(5), 585–600. DOI: 10.1007/s00281-013-0367-7.
   PubMed Web of Science ®Google Scholar
• Sica, A.; Schioppa, T.; Mantovani, A.; Allavena, P. Tumour-Associated Macrophages Are a Distinct M2 Polarised Population Promoting Tumour Progression: Potential Targets of Anti-Cancer Therapy. Euro. J. Cancer. 2006, 42(6), 717–727. DOI: 10.1016/j.ejca.2006.01.003.
   PubMed Web of Science ®Google Scholar
• Kawamura, K.; Komohara, Y.; Takaishi; et al. Detection of M2 Macrophages and Colony-Stimulating Factor 1 Expression in Serous and Mucinous Ovarian Epithelial Tumors. Pathol. Int. 2009, 59(5), 300–305. DOI: 10.1111/j.1440-1827.2009.02369.x.
   PubMed Web of Science ®Google Scholar
• Stover, C. M.; Schleypen, J.; Gronlund, J.; Speicher, M. R. Assignment1 of CD163B, the Gene Encoding M160, a Novel Scavenger Receptor, to Human Chromosome 12p13.3 by in situ Hybridization and Somatic Cell Hybrid Analysis. Cytogenet Genome Res. 2000, 90(3/4), 246. DOI: 10.1159/000056781.
   Google Scholar
• Shabo, I.; Svanvik, J. Expression of Macrophage Antigens by Tumor Cells. In Cell Fusion in Health and Disease; Springer: Dordrecht, 2011; pp. 141–150.
   Google Scholar
• Shabo, I.; Olsson, H.; Sun, X. F.; Svanvik, J. Expression of the Macrophage Antigen CD163 in Rectal Cancer Cells Is Associated with Early Local Recurrence and Reduced Survival Time. Intl J. Cancer. 2009, 125(8), 1826–1831. DOI: 10.1002/ijc.24506.
   PubMed Web of Science ®Google Scholar
• Chao, M. P.; Majeti, R.; Weissman, I. L. Programmed Cell Removal: A New Obstacle in the Road to Developing Cancer. Nat. Rev. Cancer 2012, 12(1), 58–67. DOI: 10.1038/nrc3171.
   Web of Science ®Google Scholar
• Chan, K. S.; Espinosa, I.; Chao, M.; Wong, D.; Ailles, L.; Diehn, M.; Gill, H.;Presti, J.;Chang, H. Y.; van de Rijn, M; et al. Identification, Molecular Characterization, Clinical Prognosis, and Therapeutic Targeting of Human Bladder Tumour-Initiating Cells.Proc. National Academy Sci. 2009, 106(33),14016–14021.
   PubMed Web of Science ®Google Scholar
• Majeti, R.; Chao, M. P.; Alizadeh, A. A.; Pang, W. W.; Jaiswal, S.; Gibbs, K. D.; van Rooijen, N.; Weissman, I. L. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. Cell. 2009, 138(2), 286–299. DOI: 10.1016/j.cell.2009.05.045.
   PubMed Web of Science ®Google Scholar
• Willingham, S. B.; Volkmer, J. P.; Gentles, A. J.; Sahoo, D.; Dalerba, P.; Mitra, S. S.; Wang, J.; Contreras-Trujillo, H.; Martin, R.; Cohen, J. D., et al. The CD47-Signal Regulatory Protein Alpha (SIRPa) Interaction Is a Therapeutic Target for Human Solid Tumors. Proc. Natl. Acad. Sci. Usa. 2012, 109(17), 6662–6667. DOI: 10.1073/pnas.1121623109.
   PubMed Web of Science ®Google Scholar
• Lo, J.; Lau, E. Y. T.; Ching, R. H., et al. Nuclear Factor Kappa B–Mediated CD47 Up‐Regulation Promotes Sorafenib Resistance and Its Blockade Synergizes the Effect of Sorafenib in Hepatocellular Carcinoma in Mice. Hepatology. 2015, 62(2), 534–545. DOI: 10.1002/hep.27859.
   PubMed Web of Science ®Google Scholar
• WHO Classification of Tumours Editorial Board. Breast Tumours. WHO Classification of Tumours Series, 5th Ed, Lyon (France) International Agency for research on Cancer, 2019; pp 46–47.
   Google Scholar
• Elston, C. W.; Ellis, I. O. Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience from a Large Study with Long‐Term Follow‐Up. Histopathology. 1991, 19(5), 403–410. DOI: 10.1111/j.1365-2559.1991.tb00229.x.
   PubMed Web of Science ®Google Scholar
• Amin, M. B.; Greene, F. L.; Edge, S. B.; Compton, C. C.; Gershenwald, J. E.; Brookland, R. K.; Meyer, L.; Gress, D. M.; Byrd, D. R.; Winchester, D. P., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population‐Based to a More “Personalized” Approach to Cancer Staging. CA Cancer J. Clin. 2017, 67(2), 93–99.
   PubMed Web of Science ®Google Scholar
• Lee, A. H.; Ellis, I. O. The Nottingham Prognostic Index for Invasive Carcinoma of the Breast. Pathol. Oncol. Res. 2008, 14(2), 113–115. DOI: 10.1007/s12253-008-9067-3.
   PubMed Web of Science ®Google Scholar
• Garvin, S.; Oda, H.; Arnesson, L. G.; Lindström, A.; Shabo, I. Tumour Cell Expression of CD163 Is Associated to Postoperative Radiotherapy and Poor Prognosis in Patients with Breast Cancer Treated with Breast-Conserving Surgery. J. Cancer Res. Clin. Oncol. 2018, 144(7), 1253–1263. DOI: 10.1007/s00432-018-2646-0.
   PubMed Web of Science ®Google Scholar
• Medrek, C.; Pontén, F.; Jirström, K.; Leandersson, K. The Presence of Tumour Associated Macrophages in Tumour Stroma As a Prognostic Marker for Breast Cancer Patients. BMC Cancer. 2012, 12(1), 306. DOI: 10.1186/1471-2407-12-306.
   PubMedGoogle Scholar
• Baccelli, I.; Stenzinger, A.; Vogel, V.; Pfitzner, B. M.; Klein, C.; Wallwiener, M.; Scharpff, M.; Saini, M.; Holland-Letz, T.; Sinn, H.-P.; Schneeweiss, A.; et al. Co-Expression of MET and CD47 Is a Novel Prognosticator for Survival of Luminal-Type Breast Cancer Patients. Oncotarget. 2014, 5(18), 8147. DOI: 10.18632/oncotarget.2385.
   PubMedGoogle Scholar
• Ishibashi, H.; Suzuki, T.; Suzuki, S.; Moriya, T.; Kaneko, C.; Takizawa, T.; Sunamori, M.; Handa, M.; Kondo, T.; Sasano, H., et al. Sex Steroid Hormone Receptors in Human Thymoma. J. Clin. Endocrinol. Metab. 2003, 88(5), 2309–2317.
   PubMed Web of Science ®Google Scholar
• Yang, M.; Li, Z.; Ren, M.; Li, S.; Zhang, L.; Zhang, X.; Liu, F. Stromal Infiltration of Tumor-Associated Macrophages Conferring Poor Prognosis of Patients with Basal-Like Breast Carcinoma. J. Cancer. 2018, 9(13), 2308. DOI: 10.7150/jca.25155.
   PubMed Web of Science ®Google Scholar
• Yuan, J.; He, H.; Chen, C.; Wu, J.; Rao, J.; Yan, H. Combined High Expression of CD47 and CD68 Is a Novel Prognostic Factor for Breast Cancer Patients. Cancer. Cell Inter. Dec., 2019, 19(1), 1–2. DOI: 10.1186/s12935-019-0957-0.
   PubMed Web of Science ®Google Scholar
• Solinas, C.; Carbognin, L.; De Silva, P.; Criscitiello, C.; Lambertini, M. Tumor-Infiltrating Lymphocytes in Breast Cancer According to Tumor Subtype: Current State of the Art. Breast. 2017, 35, 142–150. DOI: 10.1016/j.breast.2017.07.005.
   PubMed Web of Science ®Google Scholar
• Ribatti, D.; Tamma, R.; Annese, T. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl. Oncol. 2020, 13(6), 100773. DOI: 10.1016/j.tranon.2020.100773.
   PubMed Web of Science ®Google Scholar
• Jiang, H.; Fu, R.; Wang, H.; Li, L.; Liu, H.; Shao, Z. CD47 Is Expressed Abnormally on Hematopoietic Cells in Myelodysplastic Syndrome. Leukemia Res. 2013, 37(8), 907–910. DOI: 10.1016/j.leukres.2013.04.008.
   PubMed Web of Science ®Google Scholar
• Bianchini, G.; Balko, J. M.; Mayer, I. A.; Sanders, M. E.; Gianni, L. Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease. Nat. Rev. Clin. Oncol. 2016, 13(11), 674–690. DOI: 10.1038/nrclinonc.2016.66.
   PubMed Web of Science ®Google Scholar
• Samanta, D.; Gilkes, D. M.; Chaturvedi, P.; Xiang, L.; Semenza, G. L. Hypoxia-Inducible Factors Are Required for Chemotherapy Resistance of Breast Cancer Stem Cells. Proc. Natl. Acad. Sci. Usa 2014, 111(50), E5429–E5438. DOI: 10.1073/pnas.1421438111.
   PubMed Web of Science ®Google Scholar
• Candas-Green, D.; Xie, B.; Huang, J.; et al. Dual Blockade of CD47 and HER2 Eliminates Radioresistant Breast Cancer Cells. Nat. Commun. 2020, 11(1), 1–5.
   PubMed Web of Science ®Google Scholar
• Lindsten, T.; Hedbrant, A.; Ramberg, A.; Wijkander, J.; Solterbeck, A.; Eriksson, M.; Delbro, D.; Erlandsson, A. Effect of Macrophages on Breast Cancer Cell Proliferation, and on Expression of Hormone Receptors, uPAR and HER-2. Int. J. Oncol. 2017, 51(1), 104–114. DOI: 10.3892/ijo.2017.3996.
   PubMed Web of Science ®Google Scholar
• Stewart, D. A.; Yang, Y.; Makowski, L.; Troester, M. A. Basal-Like Breast Cancer Cells Induce Phenotypic and Genomic Changes in Macrophages. Mol. Cancer Res. 2012, 10(6), 727–738. DOI: 10.1158/1541-7786.MCR-11-0604.
   PubMed Web of Science ®Google Scholar
• Anfray, C.; Ummarino, A.; Andón, F. T.; Allavena, P. Current Strategies to Target Tumour-Associated-Macrophages to Improve Anti-Tumour Immune Responses. Cells 2020, 9(1), 46. DOI: 10.3390/cells9010046.
   Web of Science ®Google Scholar
• Castellaro, A. M.; Rodriguez-Baili, M. C.; Di Tada, C. E.; Gil, G. A. Tumour-Associated Macrophages Induce Endocrine Therapy Resistance in Er+ Breast Cancer Cells. Cancers 2019, 11(2), 189. DOI: 10.3390/cancers11020189.
   PubMed Web of Science ®Google Scholar
• Vonderheide, R. H. CD47 Blockade As Another Immune Checkpoint Therapy for Cancer. Nat. Med. 2015, 21(10), 1122–1123. DOI: 10.1038/nm.3965.
   PubMed Web of Science ®Google Scholar
• Liu, X.; Pu, Y.; Cron, K.; Deng, L.; Kline, J.; Frazier, W. A.; Xu, H.; Peng, H.; Fu, Y.-X.; Xu, M. M. CD47 Blockade Triggers T Cell–Mediated Destruction of Immunogenic Tumors. Nat. Med. 2015, 21(10), 1209–1215. DOI: 10.1038/nm.3931.
   PubMed Web of Science ®Google Scholar
• Ye, X.; Weinberg, R. A. Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015, 25(11), 675–686.
   PubMed Web of Science ®Google Scholar
• Jamiyan, T.; Kuroda, H.; Yamaguchi, R.; Abe, A.; Hayashi, M. CD68-And CD163-Positive Tumour-Associated Macrophages in Triple Negative Cancer of the Breast. Virchows Arch. 2020, 477(6), 767–775. DOI: 10.1007/s00428-020-02855-z.
   PubMed Web of Science ®Google Scholar
• Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-Associated Macrophages As Treatment Targets in Oncology. Nat. Rev. Clin. Oncol. 2017, 14(7), 399. DOI: 10.1038/nrclinonc.2016.217.
   PubMed Web of Science ®Google Scholar